Effect of EBV Infection of HRS Cells on Treatment Outcome and Survival in HD Patients
| . | EBVPositive . | EBVNegative . | P Value . |
|---|---|---|---|
| Side effects during therapy | |||
| Hematological toxicity | 18 (44%) | 57 (48%) | .79 |
| Infection | 17 (41%) | 60 (50%) | .42 |
| Neuropathy | 9 (22%) | 21 (18%) | .71 |
| Response | |||
| CR | 33 (80%) | 82 (69%) | .05 |
| PR | 4 (10%) | 31 (26%) | |
| Fail | 4 (10%) | 5 (4%) | |
| NK | 0 | 2 | |
| Survival | |||
| 2-yr survival rate | 90.2% | 81.7% | |
| Difference (95% CI) | 8.5% (−3% to 20%) | .18 | |
| 5-yr survival rate | 84.5% | 78.2% | |
| Difference (95% CI) | 6.3% (−7.9% to 20.5%) | .40 | |
| 2-yr failure-free survival | 90.2% | 74.2% | |
| Difference (95% CI) | 16% (−3.9%-28.1%) | .02 | |
| 5-yr failure-free survival | 81.5% | 68.5% | |
| Difference (95% CI) | 13% (−2.9% to 28.8%) | .13 |
| . | EBVPositive . | EBVNegative . | P Value . |
|---|---|---|---|
| Side effects during therapy | |||
| Hematological toxicity | 18 (44%) | 57 (48%) | .79 |
| Infection | 17 (41%) | 60 (50%) | .42 |
| Neuropathy | 9 (22%) | 21 (18%) | .71 |
| Response | |||
| CR | 33 (80%) | 82 (69%) | .05 |
| PR | 4 (10%) | 31 (26%) | |
| Fail | 4 (10%) | 5 (4%) | |
| NK | 0 | 2 | |
| Survival | |||
| 2-yr survival rate | 90.2% | 81.7% | |
| Difference (95% CI) | 8.5% (−3% to 20%) | .18 | |
| 5-yr survival rate | 84.5% | 78.2% | |
| Difference (95% CI) | 6.3% (−7.9% to 20.5%) | .40 | |
| 2-yr failure-free survival | 90.2% | 74.2% | |
| Difference (95% CI) | 16% (−3.9%-28.1%) | .02 | |
| 5-yr failure-free survival | 81.5% | 68.5% | |
| Difference (95% CI) | 13% (−2.9% to 28.8%) | .13 |
Abbreviations: CR, complete response; PR, partial response; NK, not known; CI, confidence interval.